Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy. “We saw an opportunity to build a sustainable business in a market that’s...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Perimeter Medical Imaging AI names Jeremy Sobotta as CEO; Tom Boon as COO
Perimeter Medical Imaging AI (TSXV:PINK; FSE:4PC) appointed Jeremy Sobotta as its new CEO and Tom Boon as its new COO, effective immediately. Mr. Sobotta was most recently Perimeter’s CFO and replaces Tom Boon as CEO...
BTIG cuts Zosano Pharma PT to $2 from $7
BTIG slashed the price target for Zosano Pharma (NASDAQ:ZSAN) to $2 from $7, citing a complete response letter about the NDA for Qtrypta, a transdermal microneedle system form of zolmitriptan in development for acute...
TG Therapeutics gets FDA fast track designation for ublituximab plus umbralisib
TG Therapeutics (NASDAQ:TGTX) received the FDA fast track designation for the ublituximab plus umbralisib for the treatment of chronic lymphocytic leukemia (CLL). Ublituximab is a glycoengineered anti-CD20 monoclonal...
Cidara updates Phase 2 rezafungin data
Cidara Therapeutics (NASDAQ:CDTX) reported new data from its Phase 2 STRIVE trial evaluating once-weekly rezafungin for the treatment of candidemia and invasive candidiasis. The trial demonstrated that rezafungin...
IntelGenx grants Tetra Bio-Pharma additional rights to Adversa mucoadhesive delivery technology
IntelGenx (TSXV:IGX; OTCQB:IGXT) granted cannabinoid-derived drug developer Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF) additional exclusive worldwide rights to IntelGenx’s Adversa mucoadhesive delivery technology. Adversa...
Inventiva odiparcil gets FDA fast track designation for mucopolysaccharidosis
Inventiva’s (PSE:IVA; NASDAQ:IVA) odiparcil received FDA fast track designation for the treatment of mucopolysaccharidosis (MPS) Type VI, a rare progressive genetic disorder. MPS is caused by deficient versions of the...
Aclaris doses first patient in Phase 2a atopic dermatitis trial
Aclaris Therapeutics (NASDAQ:ACRS) dosed the first patient in its Phase 2a trial evaluating ATI-1777 for the treatment of moderate-to-severe atopic dermatitis ATI-1777 is a topical Janus kinase (JAK) 1/3 inhibitor...
Evofem Biosciences enrolls first patient in Phase 3 STD prevention trial
Evofem Biosciences (NASDAQ:EVFM) enrolled the first patient in its Phase 3 trial evaluating EVO100 for the prevention of urogenital chlamydia and gonorrhea in women. The trial, called EVOGUARD, will enroll 1,730 women...
Selecta gets FDA rare pediatric disease designation for methylmalonic acidemia gene therapy
Selecta Biosciences’ (NASDAQ:SELB) MMA-101 received FDA rare pediatric disease designation for the treatment methylmalonic acidemia (MMA). MMA is caused by a mutation in the methylmalonyl-CoA mutase gene, which results...
Stifel starts Orthofix Medical at buy; PT $39
Stifel launched coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and price target of $39. The stock closed at $34.05 on Oct. 19. Orthofix is focused on providing medical devices, operating through the...
Stifel starts Alphatec at buy; PT $13
Stifel initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $13 price target. The stock closed at $9.88 on Oct. 19. Alphatec engages in design, development, and marketing of spinal fusion...
Stifel starts SeaSpine at buy; PT $22
Stifel launched coverage of SeaSpine Holdings (NASDAQ:SPNE) with a “buy” rating and price target of $22. The stock closed at $14.97 on Oct. 19. “After several years of uneven performance post the 2015 spin-out from...
Just a few of the companies we’ve highlighted along the way
